Form 4 for ELOX Eloxx Pharmaceuticals, Inc.

Accepted 2021-07-30 00:00:00 ET · period of report 2021-07-30 · accession 0001415889-21-003750 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-07-30	2021-07-30	ELOX	Belloff Neil S.	COO, GC, CORP SEC	F - Tax	$1.32	-459	32.7K	-1%	-$605.88
D	2021-07-30	2021-07-30	ELOX	Belloff Neil S.	COO, GC, CORP SEC	M - OptEx	$0.00	+1,563	33.2K	+5%	$0
D	2021-07-30	2021-07-30	ELOX	Belloff Neil S.	COO, GC, CORP SEC	M - OptEx	$0.00	-1,563	9,375	-14%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-07-30	F	D	459	$1.32	32,699	D	—	—
2	Common	Common Stock	2021-07-30	M	A	1,563	$0.00	33,158	D	—	—	(F1) The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock.
3	Derivative	Restricted Stock Units	2021-07-30	M	D	1,563	$0.00	9,375	D	— · — to —	1,563 Common Stock	(F3) The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. (F4) The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated with certain qualifying terminations of service or in connection with a corporate transaction. (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F1) The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock.